STOCK TITAN

Harrow, Inc. (HROW) CFO exercises 60,000 options, 26,665 shares withheld

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Harrow, Inc. reported that its president and CFO, Andrew R. Boll, exercised 60,000 stock options on 12/12/2025 at an exercise price of $3.95 per share, receiving the same number of common shares.

The options were originally granted on April 1, 2016 under the company’s 2007 Stock Incentive and Awards Plan and vested quarterly over three years. In connection with the exercise, 26,665 shares were withheld to cover the exercise price and tax liability, and the filing states this withholding did not involve any market sales or other market transactions. After these transactions, Boll beneficially owns 811,179 shares of Harrow common stock directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOLL ANDREW R.

(Last) (First) (Middle)
C/O HARROW, INC.
1A BURTON HILLS BLVD., SUITE 200

(Street)
NASHVILLE TN 37215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CFO
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/12/2025 M 60,000 A $3.95 837,844 D
Common Stock 12/12/2025 F 26,665 D $47.06 811,179 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)(1) $3.95 12/12/2025 M 60,000 (1) 04/01/2026 Common Stock 60,000 $0 0 D
Explanation of Responses:
1. Represents stock options granted to Mr. Boll on April 1, 2016 under the Issuer's 2007 Stock Incentive and Awards Plan, as amended. The stock options vested quarterly over a three-year period following the grant date. 26,665 shares were withheld to satisfy the exercise price and tax liability incident to the exercise of the stock option. Such withholding did not involve any market sales or other market transactions.
/s/ Andrew R. Boll 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Harrow, Inc. (HROW) disclose in this Form 4?

The filing shows that Andrew R. Boll, president and CFO of Harrow, Inc., exercised 60,000 stock options on 12/12/2025 at an exercise price of $3.95 per share, receiving 60,000 shares of common stock.

How many Harrow, Inc. (HROW) shares does the CFO own after this transaction?

Following the reported transactions, Andrew R. Boll beneficially owns 811,179 shares of Harrow, Inc. common stock, held in direct ownership.

What stock option grant did the Harrow, Inc. (HROW) CFO exercise?

The transaction relates to stock options granted to Mr. Boll on April 1, 2016 under Harrow’s 2007 Stock Incentive and Awards Plan, as amended. These options covered 60,000 shares, had an exercise price of $3.95, and vested quarterly over a three-year period after the grant date.

Were any Harrow, Inc. (HROW) shares sold on the open market in this transaction?

No. The filing explains that 26,665 shares were withheld to satisfy the exercise price and tax liability related to the option exercise, and that this withholding did not involve any market sales or other market transactions.

What is the role of the reporting person at Harrow, Inc. (HROW)?

The reporting person, Andrew R. Boll, is identified as an officer of Harrow, Inc., serving as the company’s president and CFO.

Harrow Health Inc

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.86B
31.08M
15.72%
57.42%
13.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE